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51.1  IntroductIon
Fusarium species are widely distributed filamentous fungi 
that commonly occur in soil, water environments, and plants. 
The genus includes both plant pathogenic and soil sapro-
phytic representatives.1 During the past decades, Fusarium 
species have emerged as increasingly important causal agents 
for opportunistic infections in human population.2
51.1.1  ClassifiCation
Fusarium, first described by Link in 1809,3 is a genus clas-
sified under the order Hypocreales, class hyphomycetes 
(Ascomycetes). Formerly included in the Deuteromycetes, 
the genus contains about 100 recognized species,4 many of 
which can induce diseases in several agriculturally impor-
tant crops and cause diseases in humans and domestic ani-
mals.5–7 Fusarium spp. are ubiquitous filamentous fungi in 
all major geographic regions of the world and are routinely 
isolated from environmental sources such as soil, plant roots, 
plant debris, and water systems.2,8 Most of the species of 
the genus have both an anamorphic (asexual) and teleomor-
phic (sexual) life cycle and exist in soils as saprophytes or 
“chlamydospores.”4
As a plant pathogen, Fusarium has been reported as the 
causal agent of major devastating diseases in most economi-
cally important plants, e.g., banana,9,10 wheat, and barley.11 
In humans, Fusarium cause four patterns of invasive infec-
tions predominantly in immunocompromised patients2,12–14: 
refractory fever of unknown origin, sinopulmonary infection, 
disseminated infection, and a variety of focal single-organ 
infections15 such as ocular infections, usually keratitis or 
endophthalmitis.16–18 The mortality rate is greater than 70% 
in systemic infections.9 In addition, an array of secondary 
metabolites is produced by Fusarium spp., which are associ-
ated with cancer and other growth defects in humans and 
animals. Interestingly, some of these secondary metabolites 
are used commercially either directly or as the starting mate-
rial for chemical synthesis of plant and animal growth pro-
moters in both first-world and second-world settings, and the 
mycotoxins produced by some of these fungi were reported 
to be used as biological weapons.19–23 Few species such as 
F. pallidoroseum can be directly used as a mycoherbicide 
against water hyacinth.24
The Fusarium classification system is developed mainly 
based on the morphology of the conidia produced by the 
representatives of the genus. Macroscopic and microscopic 
features, such as color of the colony; length and shape of the 
macroconidia; the number, shape, and arrangement of micro-
conidia; and the presence or absence of chlamydospores are 
the key features for the differentiation of Fusarium spp., and 
the main taxonomic systems have organized sections from 
the species sharing common morphological characteristics 
(Figures 51.1 through 51.3). However, speciation may be 
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difficult due to the variability between isolates and because 
the features that are required are not always well developed. 
This would best describe why although more than 100 spe-
cies have been recognized so far based on the various identi-
fication concepts, only 70 species are well described.25
The morphologically similar Fusarium species are 
grouped together as species complexes (SCs). For instance, 
the Fusarium solani species complex (FSSC) includes mor-
phologically identical isolates. Further genotypic character-
ization of isolates from this complex is laborious and usually 
not routinely performed in clinical laboratories. Members of 
this SC are usually reported in the literature as Fusarium 
solani.26 During the past few decades, there are controversies 
amongst researchers that the taxonomic system based on the 
sections sharing common morphological characteristics is of 
poor reliability compared to advanced molecular investiga-
tion methods such as random amplified polymorphic DNA 
(RAPD), amplified fragment length polymorphism (AFLP), 
restriction fragment length polymorphism (RFLP), and DNA 
sequencing.9 For instance, O’Donnell et al. reported that the 
Gibberella fujikuroi species complex (GFSC) revealed 45 
species using molecular methods for several gene targets, of 
which 23 were never reported before.27 From the clinical point 
of view, identification at the species level is important for epi-
demiological studies and may also be very important because 
some new antifungal agents exhibit variable activities against 
Fusarium isolates belonging to different species.28,29
Together, in spite of the key work done by Wollenweber 
and Reinking30 for developing a main taxonomic system, and 
the contributions during the last few decades by a significant 
number of scientists in Fusarium taxonomy, the systematic 
classification of Fusarium species has still a number of open 
question marks that need to be solved.9
51.1.2  EpidEmiology
A variety of human and animal infections due to Fusarium 
spp. are widely reported from all over the world as the genus 
does not require any strict environmental conditions for sur-
vival. For instance, Fusarium can be recovered from diverse 
sources including soil, decomposing organic matter, plant 
roots, woody plants, trees, agricultural, and non-agricultural 
substrates and are found in various geographic regions with 
hot, temperate, or cool climates. Fusarium infections are 
being increasingly recognized as life-threatening mycotic 
infections worldwide.31–33 The first documented case of dis-
seminated invasive Fusarium infection was reported in 
1973 in a child with acute leukaemia.34 Infections caused by 
Fusarium species in different organs are collectively known 
as fusariosis. The epidemiological distribution of fusariosis 
is controversial,35 as 85% of the cases until the year 2000 
were reported from Western and Mediterranean countries 
such as United States, France, Italy, and Brazil,35 and a large 
number of institutions in the world have only occasionally 
or have never documented invasive Fusarium infections.35 
The distribution of these cases only among such geographi-
cal areas cannot yet be ruled out. Among the well-described 
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FIgure 51.1  Colony morphology of Fusarium (white to violet 
pigment) from patients with Fusarium keratitis on PDA.
AQ3
FIgure  51.2  Differential interference contrast microphoto-
graph showing chlamydospores produced by Fusarium solani 
(magnification 40×).
FIgure 51.3  Gram spear showing macroconidia from corneal 
scarping of patients with Fusarium keratitis.
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70 Fusarium spp., the taxons implicated in almost half (50%) 
of the disease cases include F. solani, followed by F. oxys-
porum (14%), F. verticillioides (11%), F. moniliforme (10%), 
and F. proliferatum (5%). Further common human pathogens 
are F. dimerum, F. chlamydosporum, F. nygamai, F. napi-
forme, F. semitectum, and F. equiseti.35
It is likely that Fusarium spp. colonize patients prior to 
hospital admission and the subsequent immunosuppres-
sion and neutropenia could then result in a variety of infec-
tions.31,36 Although skin, blood, lung, and sinus infections are 
most common, other body organ systems can also be affected. 
Fusarium have been documented as etiological agents in 
localized tissue infections, including keratitis, endophthalmi-
tis, septic arthritis, cystitis, peritonitis, brain abscesses, and 
breast abscess.37–39 F. solani breast abscess was reported from 
India in an uncontrolled diabetic patient who was a paddy 
grower.38 Disseminated fusariosis with heavy involvement of 
liver and lungs was reported in a healthy farmer.40 Although 
infrequent, post-transplant invasive fusariosis is reported in 
Asian countries like India.41 In systemic fusariosis, Fusarium 
solani is the predominantly isolated taxon, followed by 
F. moniliforme, F. oxysporum, and F. proliferatum.31
Fusarium species are isolated and reported in large num-
bers from eye infections in developing countries such as 
India.42 Based on the reported case numbers, keratomycosis is 
the most frequent human infection caused by Fusarium. Most 
of the studies about fungal keratitis report the occurrence of 
Fusarium at the genus level only; however, identification of the 
Fusarium isolates at the species level would be of great impor-
tance as it is gaining consequences on clinical outcome.43
The literature provides a large amount of data about the epi-
demiology of Fusarium keratitis. The incidence and epidemi-
ological pattern of Fusarium spp. among culture-proven cases 
of keratomycosis is different from country to country (Tables 
51.1 and 51.2).2,5,14,44–107 According to a series of retrospective 
studies, Fusarium spp. can be the predominant causal agents 
of keratomycosis5,14,45,46,53–55,58–62,65–67,70,73,76,79,80,82,86,87,91,92,97,100 
besides Aspergillus spp.,47,51,56,71,83,84,88,94–96,98,99,102–104,106 
Candida spp.,44,68,78,83 and Acremonium spp.74 Tropical and 
subtropical countries are the most affected, indicating that 
climate plays an important role in determining the predomi-
nance of certain species in fungal keratitis. Certain regions 
of different continents, e.g., southern Florida, Ghana, and 
southern India, have similar climates that are favoring the 
predominance of Fusarium spp.55,79,86,100 The incidence of 
Fusarium spp. in keratomycosis may also vary with cli-
matic conditions within a single country, e.g., between dif-
ferent parts of China,59,60,62,63 Ghana,55 and India (Table 
51.2).55,86,87,88,94,98–100,103,104 Keratitis caused by Fusarium is less 
frequent in regions with temperate climates like European 
countries: only four cases have been reported from Paris, 
France, in 8 years,68 and only a single case has been diag-
nosed in Hungary.108 The most frequent taxon of Fusarium 
reported from corneal infections is the FSSC.14,58,63,64,79,86,87,109
Fusarium keratitis may occur as a mixed infection 
with bacteria, mainly Streptococcus and Staphylococcus 
spp.73,74,86,91,109 or herpes simplex virus.109
In the retrospective studies available, the proportion of 
farmers and agricultural workers among the affected patients 
was relatively high (16%–86%). Male patients were gener-
ally more frequent than females: male:female ratios were 
between 1.4:1 and 3.5:1, with the exception of a study from 
Nepal, where both sexes were equally affected.56 The average 
age of the patients in the studies ranged from 35.8 to 59 years.
Among the factors predisposing for keratomycosis, cor-
neal trauma is considered the most common, with an inci-
dence between 31.6% and 89.9%, apart from a study from 
Pennsylvania, in which only 8.3% of the patients reported 
a recent trauma.78 The reported injuries were caused by dif-
ferent traumatizing agents including plant material (corn 
stalks, grass, ground nuts, hay, kernel, onions, paddy, palm 
leaf, sugar cane, thorn, tree branch, and vegetable matter), 
animal matter (cat scratch, cow dung, cow’s tail, hair, hen 
peck, and insects), chemical gas, dust, fingernails, electric 
welding light, glass, heat injury, metal objects, mud, soil, 
stones, or physical violence. In Tanzania, positive correlation 
was found with HIV carriage: 81.2% of patients with fungal 
keratitis were HIV positive.14 Further predisposing factors 
include preexisting ocular diseases (e.g., atopic conjunctivi-
tis, chronic dacryocystitis, dry eyes, lagophthalmos, recurrent 
corneal erosion, corneal scaring, or ulcer), the use of topical 
corticosteroids, previous eye surgery, systemic diseases (e.g., 
diabetes mellitus, leprosy, or rheumatoid arthritis), as well as 
contact lens wear. During the past decade, the epidemiology 
of contact lens solution-related Fusarium keratitis has been 
studied in detail.
Risk factors associated with microbial keratitis in con-
tact lens wearers include continuous overnight wear, lower 
socioeconomic class, smoking, hypoxia, poor lens hygiene 
practice, blepharitis, diabetes mellitus, epithelial trauma, 
and steroid use, specifically in daily wear lenses.110 Contact 
lens wearers have an elevated risk for fungal keratitis, but 
the incidence of Fusarium keratitis is quite rare among this 
group of patients. There has been no report until the begin-
ning of 2006 on the association of multipurpose contact lens 
solutions with fungal keratitis. Before June 2005, the num-
ber of cases with contact lens-related fungal keratitis was 
about 3 per year in Hong Kong. In late August 2005, the 
Centre for Health Protection (CHP), Department of Health 
of Hong Kong, initiated an investigation because of the sud-
den increase in the number of cases of contact lens-related 
microbial keratitis. The initial investigation suggested that 
many fungal keratitis cases were caused by Fusarium spp. 
Great majority of the patients were disposable contact lens 
users and had reported of using a commercial multipur-
pose contact lens solution, namely Bausch&Lomb ReNu. 
Up until May 31, 2006, a total of 33 cases of contact lens-
related Fusarium keratitis were reported to the CHP. Sixty-
four percent (21/33) were female, and the age range of all 
cases was 16–51 years (mean 28 years). In a retrospective 
unmatched case–control study, Ma et al.111 focused on the 
risk factors playing a role in the development of Fusarium 
keratitis among disposable soft contact lens users. They 
successfully interviewed 32 patients, and they choose 24 
AQ5
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from them based on their case criteria. The mean age was 
30.3 and 29.2% (7/24) were male. Twenty-three of 24 used 
Bausch&Lomb contact lens solution and 21 could specify 
it as ReNu MoistureLoc. Twenty-one of the 24 stored their 
solutions in the bathroom or kitchen. Based on these data it 
can be stated that ReNu MoistureLoc was strongly connected 
to the cases of Fusarium keratitis in Hong Kong. However, 
poor lens hygiene practice was also characteristic among the 
patients. In late February 2006, the Bausch&Lomb Company 
voluntarily stopped sales of ReNu solution from the markets 
in Hong Kong. In Singapore, Wong et al.76 conducted a ret-
rospective case series study on fungal keratitis in the period 
1991–1995 at the Singapore National Eye Centre. They 
identified 29 cases of fungal keratitis. Among these cases, 
tABLe 51.1
Incidence of Fusarium spp. among culture-Proven cases of Fungal Keratitis (Based on 
Literature search)
country studied Period of study
number of 
Fungal ulcers
number of 
Fusarium Isolated reference
Australia July 1996–May 2004 35 5 (14.3%) [44]
Australia 1998–2008 16 8 (50.0%) [45]
Australia October 1999–September 2004 13 7 (53.8%) [46]
Bangladesh 11 months 51 10 (19.6%) [47]
Bangladesh 1987 7 1 (14.0%) [48]
Bangladesh 1991 107 NA (28%) [49]
Bangladesh Unknown 63 22 (34.9%) [50]
Brazil 1975–2003 265 137 (58.8%) [51]
Brazil 1983–1997 49 12 (32.0%) [52]
Brazil January 1994–December 1999 20 12 (60.0%) [53]
Brazil 2000–2004 66 44 (66.7%) [54]
Ghana, Accra (south) June 1999–May 2001 43 27 (63.0%) [55]
Nepal 1985–1987 68 8 (11.8%) [56]
Nepal August 1998–July 2001 145 45 (22.0%) [57]
Thailand (central) January 1988–December 2000 35 12 (34.3%) [5]
Nigeria 1974–1977 42 14 (33.3%) [58]
Tanzania October 1994–October 1995 32 24 (75.0%) [14]
China, Beijing (north) January1995–October 2000 498 321 (64.5%) [59]
China, Zhengzhou (central) January 1975–June 1997 615 NA (65.0%) [60]
China, Zhengzhou (central) January 2000–March 2009 1458 076 (73.8%) [61]
China, Quingdao (north) January 1996–December 1999 97 63 (64.9%) [62]
China, North January 1999–December 2004 596 437 (73.3%) [63]
China, North January 2001–December 2006 549 426 (77.6%) [64]
China 1989–2000 775 455 (58.7%) [65]
China January 2001–December 2004 681 394 (57.9%) [66]
China, Zhejiang September 2002–July 2004 61 33 (54.1%) [67]
France, Paris January 1993–January 2001 19 4 (21.1%) [68]
Iran May 2004–March 2005 7 1 (14.3%) [69]
Iran 1998–1999 29 10 (34.5%) [70]
Iran 1982–2001 27 2 (7.4%) [71]
Malaysia January 2004–April 2005 4 2 (50.0%) [72]
Paraguay April 1988–April 1989 26 11 (42.3%) [73]
Paraguay 1988–2001 136 41 (15.0%) [74]
Paraguay (children) 1988–2002 35 5 (14.3%) [75]
Singapore January 1991–December 1995 29 15 (52.0%) [76]
Thailand January 2001–December 2004 49 13 (26.5%) [77]
Pennsylvania, USA January 1991–March 1999 24 6 (25.0%) [78]
South Florida, USA January 1982–January 1992 127 79 (62.2%) [79]
South Florida, USA January 1969–December 1977 133 82 (61.6%) [80]
Florida, USA January 2004–December 2005 122 66 (54.1%) [81]
Florida, USA January 1999–June 2006 59 24 (40.7%) [82]
Minneapolis, USA January 1971–January 1981 19 3 (15.7%) [83]
Massachusetts, USA January 2004–November 2007 46 19 (41.3%) [84]
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15 were due to Fusarium species (Table 51.1). Twelve fur-
ther cases were observed in this institute from 2001 to 2004 
(unpublished data). Since March 1, 2005, there was a sig-
nificant increase of Fusarium-related eye infections among 
contact lens users. By May 2006, there were 66 reported 
cases nationwide, and 12 of these cases occurred between 
March and May, 2006. In a case study, Khor et al.17 inter-
viewed these patients. The patients were equally distributed 
by sex and the mean age was 27.1 years. Except form one, the 
patients wore disposable contact lenses. A total of 62 patients 
reported using multipurpose solutions from the same brand 
(ReNu, Bausch&Lomb, Rochester, NY). Forty-two patients 
(63.6%) reported using ReNu with MoistureLoc, 6 (9.1%) 
reported using ReNu MultiPlus, and 11 (16.7%) reported 
using an unspecified ReNu multipurpose cleaning solution. 
Based on the interview with the patients, several risk factors 
have been revealed. Isolates derived from these cases showed 
100% identity with Fusarium solani CBS490.63 based on the 
28S rRNA gene sequence. The main risk factors were the 
extended use of contact lenses after the planned replacement 
date (43.9%), the overnight use of daily wear contact lenses 
(19.7%), and swimming with contact lenses (30.3%) with 
or without the use of goggles. A case study—based on 61 
cases and 367 controls—carried out by Saw et al.112 showed 
that the risk of Fusarium keratitis was much higher in cases 
compared with control group for ReNu with MoistureLoc 
than for ReNu MultiPlus. Soft monthly disposable contact 
lenses also increased the risk of Fusarium keratitis. They 
revealed that the use of contact lenses past the replacement 
date increased the risk of Fusarium keratitis. Other factors 
such as washing of hands before replacing the lens, leaving 
the cap of the solution bottle or the lens case open, or out-
door activity were not significantly associated with Fusarium 
keratitis. On February 17, a news release warned contact lens 
wearers about the increasing incidence of fungal keratitis. On 
that same day, Bausch&Lomb voluntarily stopped all sales 
of ReNu products in Singapore. As a result of actions taken 
by the Ministry of Health and Bausch&Lomb, the number of 
cases appeared to be decreasing after March.
The Fusarium isolates responsible for the cases of con-
tact lens-related microbial keratitis17,112,113 showed distinct 
genotypes. This observation suggested that it is unlikely 
that common or clonal strains were the cause of the infec-
tions. The analysis of the F. solani and F. oxysporum isolates 
AQ6
tABLe 51.2
Incidence of Fusarium spp. in India among culture-Proven cases of Fungal 
Keratitis (Based on Literature search)
state studied Period of study
number of 
Fungal ulcers
number of 
Fusarium Isolated reference
Tamilnadu
Coimbatore (children) February 1997–January 2004 37 17 (16.8%) [85]
Madurai (south) January 1994–March 1994 155 73 (47.1%) [86]
Tiruchirapalli (south) June 1999–May 2001 353 141 (39.9%) [55]
Tiruchirapalli (south) July 1985–November 1985 40 19 (47.5%) [87]
Madras (south) 1980–1982 68 8 (11.8%) [88]
Vellore NA 7 3 (42.8%) [89]
Chidambaram July 2002–June 2005 230 74 (32.0%) [90]
Tirunelveli September 1999–March 2001 554 254 (45.8%) [91]
Tirunelveli September 1999–August 2002 1100 471 (42.8%) [92]
Tirunelveli September 1999–August 2002 1138 511 (41.6%) [93]
Rest of India
New Delhi (north) January 1999–December 2001 215 23 (10.7%) [94]
New Delhi January 2000–December 2004 77 6 (7.8%) [95]
New Delhi January 1999–June 2001 191 24 (12.5%) [96]
New Delhi NA 31 10 (32.3%) [97]
Chandigarh (north) 6 years 61 10 (16.4%) [98]
Chandigarh (north) January 1999–December 2003 34 8 (23.5%) [99]
Hyderabad (south) January 1991–December 2000 1360 506 (37.2%) [100]
Hyderabad January 1991–December 1996 557 210 (37.6%) [101]
Hyderabad February 1991–June 1995 21 3 (4.1%) [102]
Patna (east) 2 years 76 6 (7.8%) [103]
Mumbai (west) 1988–1996 387 33 (8.5%) [104]
Goa February 1993–January 1994 16 2 (12.5%) [105]
Kolkata January 2001–December 2003 623 132 (21.2%) [106]
Aurangabad NA 12 4 (33.3%) [107]
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showed that these strains are capable of forming biofilms on 
soft contact lenses under permissive conditions, but not in 
the presence of, or after recommended 4 h treatment with, 
MoistureLoc solution. These studies also concluded that 
there are no significant differences between the effectiveness 
of a freshly opened or an aged MoistureLoc solution if the 
conditions of usage are adequate.
Investigation carried out by both the U.S. Food and 
Drug Administration (FDA) and Bausch&Lomb found no 
point source of contamination in the factory. No contami-
nation was found in any bottles, and all the tested products 
were found stable and effective. However, an analysis by 
Bausch&Lomb showed that the solution can induce a breach 
in the corneal epithelium that can lead the entry of Fusarium 
into the cornea. Bausch&Lomb concluded that ReNu with 
MoistureLoc’s formulation could create biofilms that shield 
the fungus from the sterilizing agent.114,115 In the review of 
Epstein,116 the five principal elements of the Fusarium out-
break were specified as the decrease of the antimicrobial 
effect due to biocide uptake by soft contact lenses, selection 
of Fusarium due to persistence, the supported growth of 
microbes by MoistureLoc biofilm-forming capabilities and 
the nutritive properties of cellulose, chemical trauma (cor-
neal staining) upon lens insertion due to biocide release, and 
the blocking of host inflammatory response by lens. In 2006, 
the U.S. FDA initiated an inspection against Bausch&Lomb’s 
manufacturing site in Greenville, South Carolina. They found 
that the company failed to regulate the storage and transport 
temperatures in and beyond the plant. Bullock et al.117 dem-
onstrated the in vitro loss of antimicrobial activity of ReNu 
MoistureLoc against clinical isolates of Fusarium when the 
product was exposed for a prolonged time (4 week) to a tem-
perature of 60°C. With this study, they simulated the possible 
conditions to which some of the manufacturer’s bottles may 
have been exposed during storage and transport, or even, 
perhaps, after purchase. They also concluded that ReNu 
MoistureLoc was effective against Fusarium isolates after a 
10 min boiling. This suggests that the disinfectant alexidine 
inactivation is both time and temperature dependent.
Fusarium was also reported to be the cause of mycotic 
otitis of the external ear in Gabon, Central Africa,118 and 
was also found to germinate in the middle ear of agricul-
tural workers.119 Four of five cases of Fusarium osteomyeli-
tis were reported in healthy individuals following surgery or 
trauma.120 Skin lesions are present in 80% of the cases of dis-
seminated infection and they may be primary or metastatic. 
They are important for early diagnosis because of accessibil-
ity for biopsy and culture. Typical skin lesions are painful, 
erythematous, subcutaneous nodules, and plaques, which 
later undergo central necrosis.121
Fusarium species can cause localized infections of the 
nails and skin.122 Fusarium can also cause eumycetoma123 
and infection in burn wounds, colonization in burn wounds,124 
granulomas, ulcers, and panniculitis.2 Fusarium oxyspo-
rum mainly causes infection in fingernail and toenail125–128; 
however, F. solani is more frequently isolated from toenails 
only.35,128,129 More than 50% of the fusarial infections is 
involving the legs.15 Outbreaks of nosocomial fusariosis have 
also been reported. Fusarium spp., in hospital water distribu-
tion system, may result in disseminated fusariosis in immu-
nosuppressed patients.130
The possible association of the fusariosis of hospitalized 
patients with the colonization of a hospital water system by 
Fusarium was reported by Anaissie et al.131 The authors 
applied molecular typing methods, including RAPD, RFLP, 
and interrepeat (IR) PCR, and demonstrated that two patients 
were infected by F. solani strains with genotypes identical 
to that of certain environmental isolates, while the isolates 
deriving from six patients matched the isolate of another 
patient. In a similar study, there was no identity of RAPD 
patterns between clinical isolates and strains isolated from 
water samples from the hospital environment, suggesting that 
the most likely source of fusariosis was the external environ-
ment, rather than the hospital water system.132 In the study 
by Anaissie et al.,131 the two clinical isolates matching envi-
ronmental strains were collected several months before the 
environmental isolates; therefore it cannot be excluded that 
the patients may have contaminated the water systems.132
Fusarium spp. may also exist in the soil of potted plants in 
hospitals. These plants constitute a hazardous mycotic reser-
voir for nosocomial fusariosis.133
The reported major risk factors for invasive fusariosis 
include acute leukemia, bone marrow transplantation, immu-
nosuppressed state, particularly neutropenia, and the use of 
corticosteroids.134,135 The modes of entry are the respiratory 
tract, the skin, and injuries of the corneal epithelium in the 
case of mycotic keratitis. Trauma remains the major predis-
posing factor for the development of cutaneous and corneal 
infections caused by Fusarium in immunocompetent hosts.37 
Although many studies reported that skin (vascular catheters, 
periungual regions, or burns) is the main portal of entry in 
hematologic cancer with neutropenic patients, other portals 
of entries such as inhalation into the lungs or upper airways 
have also been documented.136 Intake of contaminated grain 
foods involves gastrointestinal route of infection.137 In par-
ticular, fusariosis in patients with cancer is predominantly a 
community-acquired infection, usually transmitted via the 
airborne route from the outdoor environment.131
Fusarium spp. are the only opportunistic molds that can be 
easily recovered from the blood stream.128 Histopathologically, 
Fusarium infection may mimic any other mycoses exhibiting 
moniliaceous, septate branching, or non-branching hyphae. 
Because of these morphological similarities, identification 
of the fungus obtained from cultures is required to establish 
fusarial aetiology.138
Seasonal variation has also been observed in fusari-
osis. Among patients living in rural areas, most infections 
occurred between June and September. Fifty percent of 
the eye infections and pulmonary infections peaked during 
August15,31 and 62% of the fusariosis occurred during sum-
mer months, June through August.139 Fusariosis occurs more 
commonly in males in all age group ranging from 2 to 78.31 
Fusarium can also be isolated from the conjunctival sac and 
from pharynx as a normal flora.140
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51.1.3  CliniCal fEaturEs and pathogEnEsis
The clinical features and manifestations of severe invasive 
fusariosis in immunosuppressed patients mimic those seen 
in patients with aspergillosis and are always nonspecific.141 
This can lead to inappropriate treatment regimen by the cli-
nicians.142 Also, nosocomial fusariosis has a longer latency 
period than community-acquired infection131; therefore the 
progression of disease may be unnoticed. However, the most 
common findings at the initial presentation are persistent 
fever, sinusitis, or skin lesions with a black necrotic center.31
The neutropenic patients, especially those with acute leu-
kemia, allogeneic bone marrow transplant recipients, as well 
as the patients with extensive burns or with chronic renal fail-
ure15 are at increased risk of disseminated fusariosis during 
hospitalization.122,143–146 In particular, patients with hemato-
logical malignancies account for approximately 90% of the 
reported cases of disseminated fusariosis.147 Infection typi-
cally occurs during a prolonged period of neutropenia, last-
ing up to 65 days.31,128,144,148 In neutropenic cancer patients, 
disseminated infections by Fusarium spp. usually present as 
persistent fever, fungemia, myalgia, and unresponsiveness 
to a wide spectrum of antibiotics. In immunocompromised 
patients, it may also cause eumycetoma, cause onychomy-
cosis, or harmlessly colonize the ulcers.39,138 Upon recovery 
from myleosuppression, the infection may either resolve 
completely or become chronic and localized to sinuses, 
lungs, eye, brain, joint, or muscle149 with the potential for 
relapse and dissemination upon reinstitution of cytotoxic 
chemotherapy.128 Other presentations of invasive fusariosis 
in compromised hosts include osteomyelitis, septic arthritis, 
myositis, foot abscesses, endocarditis, myocarditis, external 
otitis, peritonitis, brain abscesses, cystitis, meningoencepha-
litis, and chronic hepatic infection.2,32,134,120,150–156
As mentioned previously, infections caused by this fun-
gus can mimic aspergillosis.122 However, some distinct 
differences can be seen, such as an increased incidence of 
skin and subcutaneous lesions and a positive blood culture, 
mainly in the first days of fever, for patients with dissemi-
nated fusariosis.136,143 In contrast to invasive aspergillosis, 
the blood cultures are positive in disseminated fusariosis in 
up to 50%–70% of the cases.32,145,157 Skin lesions, the hall-
marks of disseminated fusariosis, occur in 60%–90% of the 
cases, compared with a rare occurrence (10%) of such lesions 
in disseminated aspergillosis.2,158,159 Patients with neutro-
penia have a higher rate of disseminated skin lesions com-
pared with nonneutropenic immunocompromised patients.37 
Subcutaneous nodules, palpable and nonpalpable purpura, 
red or gray macules, red or gray papules, macules or papules 
with progressive central necrosis with central, flaccid pus-
tules, vesicles, and hemorrhagic bullae are types of lesions 
seen in patients with disseminated fusariosis.2,148,159 These 
skin lesions can involve any site, with predominance on the 
extremities.37,159 The lesions, especially the subcutaneous 
nodules, are often tender159 and most patients have lesions at 
various stages of evolution.31,159 The number of disseminated 
skin lesions is variable and ranges between 4 and more than 
30.159 Skin lesions are important potential sources of diag-
nostic tissue in some patients with fusariosis.37
When four different taxa of Fusarium were tested in 
murine model, F. solani was found to be the most viru-
lent species.39,160 The production of secondary metabolites, 
mycotoxins are mainly associated with the pathogenesis.2 
Common mycotoxins produced by Fusarium spp. include 
moniliformin, zearalenone, trichothecenes (deoxynivalenol, 
nivalenol, and diacetoxyscirpenol), fumonisins, T-2 toxin, 
and fusaric acid.161 Among these, trichothecenes, zearele-
nones, and fumonisins are the most notorious.162 Ingestion 
of grains contaminated with these toxins may give rise to 
allergic symptoms or be carcinogenic in long-term consump-
tion. They are known to cause myelosuppression through 
toxin production.126 Furthermore, exposure to fumonisin may 
lead to human birth defects.163 The best example is alimen-
tary toxic aleukia, which has been associated with the inges-
tion of overwintered cereal grains colonized by the toxigenic 
F. sporotrichioides and F. poae.164 The toxin produced by 
these organisms, called T-2 toxin, is considered as the princi-
pal component responsible for the acquisition of alimentary 
toxic aleukia. The first recognized trichothecene mycotoxi-
cosis was alimentary toxic aleukia in the USSR in 1932 and 
the mortality rate was 60%.165 Common manifestations of 
trichothecene toxicity are depression of immune responses 
and nausea. In vitro, they impair cellular immunity and 
decrease the humoral response to T-dependent antigens.166 
Experimental injection of T-2 toxin resulted in cardiomyopa-
thy.167 Zearalenone is mainly produced by F. graminearum, 
and it produces estrogenic effects such as infertility, vul-
val edema, vaginal prolapsed, and mammary hypertrophy 
in females and feminization of males—atrophy of testes 
and enlargement of mammary glands. F. moniliforme and 
F. proliferatum produce fumonisin toxin in maize which 
may cause esophageal cancer.168 In India, a single outbreak of 
acute foodborne disease possibly caused by fumonisin B1 has 
been reported. The main features of the disease were tran-
sient abdominal pain, borborygmus, and diarrhea.169 Studies 
on reduction or elimination of Fusarium spp. and mycotoxins 
from contaminated agricultural and food commodities are in 
progress.170–172 As a saprophytic nature of the genus, it can 
easily invade in the neutropenic patient and develop invasive 
fusariosis. In addition, prolonged usage of corticosteroids 
and antibiotics in patients with organ transplantation, silastic 
catheters, and infections of central venous catheters (CVCs), 
continuous ambulatory peritoneal dialysis (CAPD) catheters, 
and contact lenses have been reported.2
Keratomycosis, one of the most frequent human infec-
tions caused by Fusarium, is a suppurative, usually ulcerative 
corneal disease, most frequently occurring as a localized 
infection.173 Infection is exogenous in most of the cases, the 
pathogen is entering through the epithelium of the cornea. 
Patients usually present with photophobia and discharge 
from the eyes. A persistent infiltrate is often present at the 
site of superficial injury, which gradually increases in size 
and density. The cornea becomes slightly thickened, and 
satellite lesions may develop peripheral to the focal area of 
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infiltrations. The signs of inflammation are minimal in com-
parison with bacterial keratitis.
Fusarium species are often resistant to most of the antifun-
gal agents, and F. solani is the most resistant species within 
the genus.29,174,175 In vitro resistance has been documented 
against the antifungal agents miconazole, ketoconazole, 
5-fluorocytosine, fluconazole, itraconazole, and nikkomycin 
Z.28,122,128,176–181 However, amphotericin B (AMB) has been 
shown to be the mainstay in the treatment of fusariosis.182 
In view of the inherent resistance of Fusarium spp. to most 
antifungal agents, AMB-based combination regimens have 
also been suggested or used for fusariosis.128 Natamycin 
is also active against Fusarium spp. both in vitro and in 
vivo,25,26,123,124 and in combination with AMB it has been the 
mainstay of treatment for Fusarium keratitis.123 However, its 
toxicity precludes its systemic use in clinical practice although 
topical application in powder form could halt the progres-
sion of fusariosis in pediatric patients with severe burns.125 
Ketoconazole, miconazole, fluconazole, flucytosine, and itra-
conazole have no in vitro activity against Fusarium spp.29,174 
However, the newer broad-spectrum triazoles, voriconazole 
(VRC), posaconazole, and ravuconazole have variable 
in vitro activities against Fusarium spp. and show prom-
ise for the management of fusariosis.29,126–129,174,175,178,183–187 
Posaconazole, a broad-spectrum triazole, is active against 
Fusarium species both in vitro and in animal models.29,174 
Overall, due to the inherent resistance of Fusarium spp. 
against most of the current group of antifungal agents and the 
profound solid state of immunosuppression in patients who 
typically develop fusariosis, the currently available therapeu-
tic strategies for invasive fusariosis particularly in heavily 
immunocompromised patients have less solutions.2,5–9,25
51.1.4  diagnosis
51.1.4.1  conventional techniques
Identification of Fusarium species is traditionally carried out 
by the investigation of macro- and micromorphology. The 
most commonly used macromorphological characters are 
the colony morphology on the upper and lower surface of 
the medium, the linear or radial growth rates, and the pig-
mentation.2,188,189 These characters are useful for describing a 
species under standard environmental conditions (e.g., light, 
temperature, and substrates)2,190; however, they should be 
applied with caution as they may vary between the isolates 
of a certain species, especially among clinically important 
ones.2
The micromorphological characters of the three types of 
spores (macroconidia, microconidia, and chlamydospores) 
are more suitable criteria for the differentiation of Fusarium 
species.2,189 The absence or presence of one type of them is 
a key characteristic. The shape of macroconidia (which are 
formed in sporodochia) is the main distinguishing character, 
as it is relatively consistent and stable on natural substrates 
and under standard environmental conditions, in contrast to 
the size of macroconidia, which is varying within an indi-
vidual species.2,189,191 Macroconidia vary in shape from short 
and squat to highly curved and elongate with needle-like 
spores.189 Further key macroconidial characters are the num-
ber of septa, and the shape of the apical and basal cells: the 
apical cell of the macroconidium may be rounded, needle-
like, or whip-like and the basal cell may be barely notched 
or resemble an upside-down foot.189 The presence or absence 
of microconidia with various shapes and sizes (which are 
formed in aerial mycelium) is a primary distinguishing char-
acter in Fusarium taxonomy. They may be produced singly, 
in false heads only, or in false heads and chains.2,189 Their 
shapes may be napiform, oval, pyriform, clavate, fusiform, 
or globose.2 The microconidiophores can be monophialidic 
only or both mono- and polyphialidic.2,189 Monophialides 
have a single opening in the conidiogenous cell, while 
polyphialides have two or more.189 Chlamydospores are more 
common in the older cultures, their presence or absence is 
a distinguishing character. These thick-walled, verrucose, 
light-colored spores filled with lipid-like material can be 
formed singly, in pairs, in clumps, or in chains in the hyphae 
above or below the agar surface.2,189 Their outer wall can be 
smooth or rough.2 Pseudochlamydospores were described by 
Marasas et al.164 in the case of F. andiyazi. They are thin and 
smooth walled and can be found singly or in short chains in 
the hyphae.164
A lot of secondary characters can be used in Fusarium 
identification, e.g., the presence or absence of sporodochia, 
sclerotia, and stroma2; toxins and other metabolites192; or 
odor.189 Their usage is limited, as these data are not com-
monly available for routine diagnoses.189
Beyond morphology, the studies of sexual cross-fertility 
can be used for the identification of Fusarium species.189,193 
Due to the disadvantages of this technique (that it is slow and 
needs adequate incubator space), it is not recommended for 
the purposes of clinical diagnosis.
51.1.4.2  Molecular techniques
Molecular techniques may help us to avoid the misidentifi-
cation of Fusarium based on their macro- and microscopic 
observation. The main advantage of the identification by 
molecular techniques is that they do not require viable organ-
ism or sporulation; therefore, they enable a rapid diagnosis.194
Several methods are available for molecular identifica-
tion of Fusarium species, and they have been continuously 
improving by new methods. Fingerprint techniques, like 
RFLP, AFLP, etc., are useful to identify an unknown strain, 
if a set of reference strains are available.25,189 Their advan-
tages are that DNA sequencing is not required and these 
methods are also appropriate to reveal the evolutionary dis-
tance between the investigated isolates.25,189 DNA sequences 
of the internal transcribed spacer (ITS) regions of the ribo-
somal RNA gene cluster are not very useful in distinguish-
ing Fusarium species.195 The sequencing of partial fragments 
from other amplified genes and their comparison with simi-
lar sequences available in the GenBank database is a com-
monly followed strategy for Fusarium identification.25,189,196 
The most frequently used targets are the β-tubulin gene, the 
translation elongation factor 1α gene (tef1), and the histon 
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gene.25,189,196 For rapid group- or species-level identification, 
specific primer pairs for PCR are described in the litera-
ture.197,198 Real-time PCR detection protocols were evaluated 
for fast detection and identification based on the differences 
between the tef-encoding genes199 and the genes involved in 
mycotoxin biosynthesis; however, this approach is not yet 
available for all species.200–204 A DNA microarray was also 
developed for the easy and fast detection and identification 
of the fungal genus Fusarium based on the recent phyloge-
netic analyses of tef1.205 Investigation of the intergenic spacer 
(IGS) regions with molecular methods is useful to resolve the 
identified species into various subgroups.206
51.2  Methods
51.2.1  samplE prEparation
In the case of filamentous fungi, conventional DNA extraction 
methods are well suited for the preparation of total genomic 
DNA.207 Disadvantages of these techniques are that they are 
slow, and relatively high amount of sample is needed. In the 
studies reviewed in the previous sections, commercial DNA 
purification kits were used for rapid and safe sample preparation.
Media and culture conditions: The following three media 
are preferred for morphological identification of Fusarium 
species: potato dextrose agar medium (PDA, 50% potato fil-
trate obtained by boiling 300 g diced potato in 500 mL water 
and filtering, 20 g sucrose) for the investigation of colony mor-
phology and pigmentation; and for measuring of the growth 
rates189; carnation leaf-piece agar medium (CLA; sterile 
3–5 mm carnation leaf pieces in agar) for the investigation of 
macrocinidia208; and “Spezieller Nährstoffarmer agar” (SNA, 
1 g KH2PO4, 1 g KNO3, 0.5 g MgSO4 × 7 H2O, 0.5 g KCl, 0.2 g 
glucose, 0.2 g sucrose) for the investigation of microconidia 
and chlamydospores209 (all media are given for 1 L and con-
tain 20 g agar). After incubation at 20°C–25°C for 7–10 days 
in the presence of light, particularly some exposure to UV 
(black) light (λ = 310–360 nm), Fusarium isolates grow well 
and form conidia.189 Artificial daylight (12 h light/12 h dark) 
is often used, although total darkness or continuous light is 
necessary for the evaluation of critical diagnostic characters 
of some species.209 In the case of PDA cultures, the presence 
of light is not essential, but it is increasing the production and 
total amount of pigment. On the other hand, light is important 
for CLA cultures as it increases the production of sporodo-
chia.189 Genomic DNA can be extracted from mycelia grown 
either on solid or in liquid malt extract medium after incuba-
tion at 20°C–25°C for 7 days.
Microscopy sample preparation: Microscopy samples can 
be made from colonies grown on PDA, CLA, and SNA after 
incubation at 20°C–25°C for 7–10 days in the presence of light.
Genomic DNA preparation: Genomic DNA can be 
extracted from mycelia grown either on solid or in liquid 
PDA medium after incubation at 20°C–25°C for 5–7 days. 
Beyond conventional DNA preparation methods,25,194 com-
mercial DNA purification kits can be used for rapid sample 
preparation.
51.2.2  dEtECtion proCEdurEs
51.2.2.1   Morphological Identification 
of Fusarium species
The steps of identification based on the macro- and micro-
morphological characters were described by Summerell 
et al.189 and Leslie and Summerell.25
Procedure
 1. Plate the strain onto PDA, CLA, and SNA medium 
and incubate it at 20°C–25°C for 7–10 days in the 
presence of light.
 2. Observe the colony morphology, the growth rates, 
the presence of sporodochia, and the color of the 
culture and of the produced pigments in PDA.
 3. Examine under light microscope the shape and size 
of macroconidia and chlamydospore production on 
CLA.
 4. Investigate under light microscope the shape, size, 
and formation of microconidia, their conidiogenous 
cells, and chlamydospore production on SNA.
 5. Examine the growth rates based on linear growth in 
a race tube as described by Ryan et al.,211 and/or in a 
Petri-dish as described by Burgess et al.212
 6. Organize the data with the use of a recording 
sheet.25,212
 7. Make the identification using a manual. The four 
most commonly used manuals for morphology iden-
tification were written by Gerlach and Nirenberg,213 
Nelson et al.,191 Burgess et al.,212 and Leslie and 
Summerell.25
The main macromorphological characteristic features 
are25,191,212,213
 a. Abundance and color of aerial mycelium
 b. Pigmentation
 c. Growth rate
The main micromorphological characteristic features 
are25,191,212,213
 d. Macroconidia: size, shape, number of septa, shape 
of apical and basal cell
 e. Microconidia: size, shape, number of cells, for-
mation, nature of conidiogenous cells, and 
conidiophores
 f. Chlamydospores: presence or absence, formation
51.2.2.2  Molecular Identification of Fusarium species
51.2.2.2.1 Genus-Specific Identification
51.2.2.2.1.1  PCR Protocol of Hue et al.197 PCR meth-
ods for rapid and reliable identification of Fusarium spe-
cies isolated from clinical samples were evaluated by Hue et 
al.197 and Hennequin et al.214 Hue et al.197 described a method 
appropriate for the preparation of PCR templates from 
Fusarium-containing blood and performed PCR with prim-
ers designed for the ribosomal RNA genes (rDNAs) based on 
a large number of isolates belonging to the genus Fusarium. 
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Primers P28SL (5′-ACA AAT TAC AAC TCG GGC CCG 
AGA-3′) and P58SL (5′-AGT ATT CTG GCG GGC ATG 
CCT GT-3′) amplified a fragment of 329 bp containing ITS2 
and a portion of 5.8S and 28S rDNA. To avoid false-negative 
results, a positive internal control was used from a part of λ 
phage DNA. It was amplified by two primers (C1, 5′-ACA 
AAT TAC AAC TCG GGC CCG AGA CCA CAG CGC-
3′ and C2, 5′-AGT ATT CTG GCG GGC ATG CCT GTG 
TAC AAC TGG-3′), whose 3′ ends correspond to the λ DNA 
while the 5′ ends correspond to the primers used in the PCR 
amplification. The PCR reaction resulted in a 517 bp frag-
ment which contains the Fusarium sequence at the ends, than 
it was amplified with the Fusarium primers.
Procedure197:
 1. Lyze the cells with a commercial genomic blood 
DNA purification kit. Mix it with 200 mL of 
enzyme buffer (0.9 M sorbitol, 0.1 M Tris, 0.1 M 
EDTA) and 20 mL of lyticase and incubate the 
samples at 37°C for 90 min. Treat the sample with 
proteinase K (10 mL, 20 mg/mL) and incubate it at 
55°C for 30 min. Add 5 μL of RNase and incubate 
the sample at 37°C for 30 min. Extract the DNA 
with a commercial genomic blood DNA purifica-
tion kit.
 2. Prepare the reaction mixture according to the man-
ufacturer’s instructions. Use 1 ng of template DNA 
per reaction mixture.
 3. Perform the first PCR in a thermocycler using the 
following reaction conditions: 94°C for 5 min; 40 
cycles of 94°C, 68°C, and 72°C for 1 min each; and 
a final 72°C for 10 min. Include the positive internal 
control.
 4. Visualize the PCR products after electrophoresis on 
2% agarose gel stained with ethidium bromide and 
run in 1 × TAE (Tris-acetate-EDTA) buffer.
51.2.2.2.1.2  PCR Protocol of Hennequin et 
al.214 Hennequin et al.214 designed a primer pair based on 
the 28S rDNA sequences of Fusarium species associated 
with human infections. In contrast to the DNA from unre-
lated genera, the primers Fus1 (5′-TGA AAT CTG GCT 
CTC GGG-3′) and Fus2 (5′-CAT GCG CGA ACC TCA 
GTC-3′) amplified a 480 bp fragment from the DNA extracts 
of Fusarium strains and of the members of related genera 
Acremonium and Cylindrocarpon.
Procedure214:
 1. Prepare the reaction mixture in a final volume of 
50 μL containing 5 μL genomic DNA template, 
10 mM Tris–HCl, 50 mM KCl, 2.5 mM MgCl2, 
0.01% (w/v) gelatin, 5 μL of DNA, 0.25 μM of each 
primers, 0.2 mM of each deoxynucleoside triphos-
phates (dNTPs), and 0.3 U of Taq polymerase.
 2. Perform the PCR in a thermocycler using the fol-
lowing reaction conditions: 94°C for 10 min; 35 
cycles of 94°C for 30 s, 64°C for 90 s, and 72°C for 
90 s; and a final 72°C for 10 min.
 3. Visualize the PCR products after electrophoresis on 
1% agarose gels stained with ethidium bromide and 
run in 1 × TAE buffer.
51.2.2.2.2 Species-Specific Identification
Fusarium species can be identified at the species level by 
sequencing of amplified gene fragments and comparing the 
sequences with similar ones available in sequence databases 
(FUSARIUM-ID, GenBank, EMBL, and DDBJ) using a 
Basic Local Alignment Search Tool (BLAST) search.
51.2.2.2.2.1  β-Tubulin Gene PCR Protocol 1206 Yli-
Mattila et al.206 used a universal forward primer (T1: 5′-ATG 
CGT GAG ATT GTA AGT-3′)215 and a specific reverse 
primer (tub-conrev T22: 5′-TGA CCG AAA ACG AAG TTG 
TC-3′) for amplifying a fragment with the first two introns of 
the β-tubulin-encoding gene.206
 1. Prepare the reaction mixture containing 5–50 ng 
genomic DNA, 2.5 mM MgCl2, 10 mM Tris–HCl 
(pH 8.8), 50 mM KCl, 0.1% (w/v) Triton X-100, 
0.4 μM of each primer, 0.12 mM of each dNTP, 3 U 
of Taq polymerase.
 2. Perform the PCR in a thermocycler using the fol-
lowing reaction conditions: 1 min at 94°C; 30 cycles 
of 94°C, 51°C, and 74°C for 1 min each; and a final 
74°C for 7 min.
 3. Visualize the PCR products after electrophoresis on 
1% agarose gels stained with ethidium bromide and 
run in 1 × TAE buffer.
 4. Purify the PCR products with a commercial PCR 
DNA purification kit.
 5. After the sequencing of the PCR product, compare 
it with the β-tubulin sequences available in the 
GenBank database using a BLAST search.
Amplification of a partial β-tubulin gene fragment was 
carried out by Chung et al.216 using a specific primer pair, 
FU-tubulin3 (5′-CGA GCC CGG TAC CAT GGA CG-3′) and 
FU-tubulin2 (5′-GGT CGC CGT AAG AGG GGT TGG-3′).
51.2.2.2.2.2 β-Tubulin Gene PCR Protocol 2216
 1. Prepare the reaction mixture in a final volume of 
20 μL containing 5–50 ng genomic DNA, 0.2 μM of 
each primer, 0.25 mM of each dNTP, 1 U of Ex Taq 
polymerase and Ex Taq reaction buffer (containing 
2 mM MgCl2).
 2. Perform the PCR in a thermocycler using the fol-
lowing reaction conditions: 94°C for 3 min; 35 
cycles of 94°C for 1 min, 60°C for 30 s, and 72°C for 
2 min; and a final 72°C for 5 min.
 3. Visualize the PCR products after electrophoresis on 
1% agarose gels stained with ethidium bromide and 
run in 1 × TAE buffer.
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 4. Purify the PCR products with a commercial PCR 
DNA purification kit.
 5. After the sequencing of the PCR product, compare 
it with the β-tubulin sequences available in the 
GenBank database using a BLAST search.
51.2.2.2.2.3  Translation Elongation Factor 1α Gene (tef1) 
PCR The tef1 gene has high phylogenetic utility at the spe-
cies level in Fusarium.196 Several universal primers have 
been designed that work across the phylogenetic breadth of 
the genus.196,217 Geiser et al.196 created the first generation of a 
database (FUSARIUM-ID v.1.0, http://fcgp.fusariumdb.org/
intro.php), which contains more than 400 sequences repre-
senting a phylogenetically diverse selection of tef1 sequences 
from the Fusarium genus.217
Procedure196,217
 1. Perform a standard PCR protocol with an anneal-
ing temperature of 53°C to amplify the tef1 gene 
region using forward primer ef1 (5′-ATG GGT 
AAG GA(A/G) GAC AAG AC-3′) and reverse 
primer ef2 (5′-GGA (G/A)GT ACC AGT (G/C)AT 
CAT GTT-3′).
 2. Visualize the ∼700 bp PCR products after electro-
phoresis on 1% agarose gel stained with ethidium 
bromide and run in 1 × TAE buffer.
 3. Purify the PCR products with a commercial PCR 
DNA purification kit.
 4. After the sequencing of the PCR product, compare 
it with the tef1 sequences available in the Fusarium 
database (http://isolate.fusariumdb.org/) using a 
BLAST search.
51.2.2.2.2.4  Histon-Encoding Gene PCR Steenkamp et 
al.218 performed PCR for amplification of a histone H3 gene 
fragment ranging from 519 to 527 bp with the primers H3-1a 
(5′-ACT AAG CAG ACC GCC CGC AGG-3′) and H3-1b 
 (5′-GCG GGC GAG CTG GAT GTC CTT-3′).219
Procedure218
 1. Prepare the reaction mixture containing 0.25 ng 
genomic DNA/0.05 U Taq polymerase, 2.5 mM 
MgCl2, 1 × reaction buffer, 0.2 μM of each primer, 
0.25 mM of each dNTPs.
 2. Perform the PCR in a thermocycler using the fol-
lowing reaction conditions: 92°C for 1 min; 30 
cycles of 92°C, 68°C, and 72°C for 1 min each; and 
a final 72°C for 5 min.
 3. Visualize the PCR products after electrophoresis on 
1% agarose gel stained with ethidium bromide and 
run in 1 × TAE buffer.
 4. Purify the PCR products with a commercial PCR 
DNA purification kit.
 5. After the sequencing of the PCR product, compare 
it with the histone H3 sequences available in the 
GenBank database using a BLAST search.
51.2.2.2.2.5  ITS Sequence PCR Oechsler et al.220 
designed primers for the end of the 18S ribosomal DNA 
(F18A: 5′-GCG GAG GGA TCA TTA CCG AGT T-3′) and 
the beginning of the 28S rRNA (F28S: 5′-CAG CGG GTA 
TTC CTA CCT GATC-3′) of the target Fusarium species, 
and amplified with them the ITS region comprising ITS1, 
5.8S rRNA, and ITS2. Although previous ITS analyses were 
not very useful for distinguishing Fusarium species, the 
sequence data from this study correlated well with the mor-
phologic classification. The authors suggested the feasibility 
of Fusarium detection and identification at the species level 
from ocular sources using the sequence of the ITS region.
Procedure220
 1. Prepare the reaction mixture for a standard PCR 
protocol in the final volume of 25 μL containing 
200 ng DNA template.
 2. Perform the PCR in a thermocycler using the follow-
ing reaction conditions: 95°C for 3 min; 45 cycles of 
95°C for 30 s, 55°C for 30 s, and 68°C for 2 min.
 3. Visualize the PCR products after electrophoresis in 
1% agarose gels stained with ethidium bromide and 
run in 1 × TAE buffer.
 4. Purify the PCR products with a commercial PCR 
DNA purification kit.
 5. After the sequencing of the PCR product, compare 
it with the ITS sequences available in the GenBank 
database using a BLAST search.
51.2.2.2.2.6  F. oxysporum- and F. solani-Specific 
PCR There are a lot of species-specific primer pairs in the 
literature for rapid and reliable identification of Fusarium 
species.198,214,217,221 Ghignone and Migheli198 collected the 
species-specific primers for the detection of phytophatogenic 
fungi and created a continuously improving database from 
them (http://www.sppadbase.com/). This database contains 
primers for identification of some human pathogenic mem-
bers of the Fusarium genus and references where the proto-
cols are described.
Hue et al.197 designed primer pairs for specific detection 
of five clinically important Fusarium species derived from 
human sources. Only the OX 31 (5′-TGA CTT GGA TGA 
GAC CTT GGC G-3′) and OX 32 (5′-CAG GAT TTA CCG 
ACA CAG CTT TTG-3′) primer pair was specific for the inves-
tigated F. oxysporum strains (annealing temperature = 66°C), 
while the SOL 31 (5′-GCT ACC GAG GCC ATC AAT TCA 
TG-3′) and SOL 32 (5′-TGA TGT TGT ACT TCT CCT TGC 
CC-3′) primer pair was specific for four of the five tested 
F. solani strains (annealing temperature = 66°C). The proce-
dure and methodology are described in Section 51.2.2.2.1.
51.3   concLusIon And Future 
PersPectIves
As human and animal diseases due to Fusarium spp. have 
become increasingly common, there is an urgent need to 
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develop rapid, sensitive, and specific diagnostic methods for 
these organisms. Correct identification of Fusarium organ-
isms to species/clonal level is essential for the control of 
human and plant fusarial diseases. Considering the fact that 
the morphological features of Fusarium at both the genus and 
species level are diverse and similar to those of other fungal 
genera/species, it has been a challenge to identify these organ-
isms precisely. To ensure effective solutions against prob-
lems of Fusarium etiology, it is critical to develop common 
and suitable identification systems for Fusarium taxonomy 
using a combination of conventional culture, macroscopic 
and microscopic characteristics, and molecular methods. For 
clinical strains of Fusarium, antimicrobial susceptibility pat-
terns of the new isolates can be compared with the confirmed 
patterns for additional understanding about the species and 
will also help select most appropriate chemotherapy. Further 
analysis of Fusarium whole-genome sequences will facili-
tate comparison and reconfirmation of the species/clones in 
future.
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